1887

Access Microbiology open research platform logo

Volume 2, Issue 7

Using next-generation sequencing of microRNAs to identify host and/or pathogen nucleic acid signatures in samples from children with biliary atresia – a pilot study Open Access

Abstract

Biliary atresia (BA) is a progressive disease affecting infants resulting in inflammatory obliteration and fibrosis of the extra- and intra-hepatic biliary tree. BA may be grouped into type 1 isolated; type 2 syndromic, where other congenital malformations may be present; type 3 cystic BA, where there is cyst formation within an otherwise obliterated biliary tree; and cytomegalovirus-associated BA. The cause of BA is unclear, with immune dysregulation, inflammation and infection, particularly with cytomegalovirus (CMV), all implicated. In this study a total of 50/67 samples were tested for CMV DNA using quantitative real-time PCR. Ten liver tissue and 8 bile samples from 10 patients representing the range of BA types were also analysed by next-generation sequencing. CMV DNA was found in 8/50 (16 %) patients and a total of 265 differentially expressed microRNAs were identified. No statistically significant differences between the various types of BA were found. However, differences were identified in the expression patterns of 110 microRNAs in bile and liver tissue samples (<0.05). A small number of bacterial and viral sequences were found, although their relevance to BA remains to be determined. No direct evidence of viral causes of BA were found, although clear evidence of microRNAs associated with hepatocyte and cholangiocyte differentiation together with fibrosis and inflammation were identified. These include miR-30 and the miR-23 cluster (liver and bile duct development) and miR-29, miR-483, miR-181, miR-199 and miR-200 (inflammation and fibrosis).

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): biliary atresia , microRNA and next-generation sequencing
Funding
This study was supported by the:
  • Children's Liver Disease Foundation (Award NL1752)
    • Principle Award Recipient: Melvyn Smith
© 2020 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/acmi/10.1099/acmi.0.000127
2020-06-12
2024-05-04
Loading full text...

Full text loading...

/deliver/fulltext/acmi/2/7/acmi000127.html?itemId=/content/journal/acmi/10.1099/acmi.0.000127&mimeType=html&fmt=ahah

References

  1. Livesey E, Borja MC, Sharif K, Alizai N, McClean P et al. Epidemiology of biliary atresia in England and Wales (1999-2006). Arch Dis Child Fetal Neonatal Ed 2009; 94:F451–F455 [View Article]
     [Google Scholar]
  2. Davenport M, De Ville de Goyet J, Stringer MD, Mieli-Vergani G, Kelly DA et al. Seamless management of biliary atresia in England and Wales (1999-2002). Lancet 2004; 363:1354–1357 [View Article][PubMed]
     [Google Scholar]
  3. Asai A, Miethke A, Bezerra JA. Pathogenesis of biliary atresia: defining biology to understand clinical phenotypes. Nat Rev Gastroenterol Hepatol 2015; 12:342–352 [View Article][PubMed]
     [Google Scholar]
  4. Davenport M. Biliary atresia: clinical aspects. Semin Pediatr Surg 2012; 21:175–184 [View Article][PubMed]
     [Google Scholar]
  5. Xu Y, Yu J, Zhang R, Yin Y, Ye J et al. The perinatal infection of cytomegalovirus is an important etiology for biliary atresia in China. Clin Pediatr 2012; 51:109–113 [View Article][PubMed]
     [Google Scholar]
  6. Fischler B, Svensson JF, Nemeth A. Early cytomegalovirus infection and the long-term outcome of biliary atresia. Acta Paediatr 2009; 98:1600–1602 [View Article][PubMed]
     [Google Scholar]
  7. Bessho K, Bezerra JA. Biliary atresia: will blocking inflammation tame the disease?. Annu Rev Med 2011; 62:171–185 [View Article][PubMed]
     [Google Scholar]
  8. Bezerra JA. Biliary atresia--translational research on key molecular processes regulating biliary injury and obstruction. Chang Gung Med J 2006; 29:222–230[PubMed]
     [Google Scholar]
  9. Mack CL. The pathogenesis of biliary atresia: evidence for a virus-induced autoimmune disease. Semin Liver Dis 2007; 27:233–242 [View Article][PubMed]
     [Google Scholar]
  10. Ahmed AF, Nio M, Ohtani H, Nagura H, Ohi R. Clinical significance of c-kit expression in biliary atresia. Pediatr Surg Int 2001; 17:601–603 [View Article][PubMed]
     [Google Scholar]
  11. Bezerra JA, Tiao G, Ryckman FC, Alonso M, Sabla GE et al. Genetic induction of proinflammatory immunity in children with biliary atresia. Lancet 2002; 360:1653–1659 [View Article][PubMed]
     [Google Scholar]
  12. Bill AH, Haas JE, Foster GL. Biliary atresia: histopathologic observations and reflections upon its natural history. J Pediatr Surg 1977; 12:977–982 [View Article][PubMed]
     [Google Scholar]
  13. Broomé U, Nemeth A, Hultcrantz R, Scheynius A. Different expression of HLA-DR and ICAM-1 in livers from patients with biliary atresia and Byler's disease. J Hepatol 1997; 26:857–862 [View Article]
     [Google Scholar]
  14. Davenport M, Gonde C, Redkar R, Koukoulis G, Tredger M et al. Immunohistochemistry of the liver and biliary tree in extrahepatic biliary atresia. J Pediatr Surg 2001; 36:1017–1025 [View Article][PubMed]
     [Google Scholar]
  15. Mack CL, Tucker RM, Sokol RJ, Karrer FM, Kotzin BL et al. Biliary atresia is associated with CD4+ Th1 cell-mediated portal tract inflammation. Pediatr Res 2004; 56:79–87 [View Article][PubMed]
     [Google Scholar]
  16. Ohya T, Fujimoto T, Shimomura H, Miyano T. Degeneration of intrahepatic bile duct with lymphocyte infiltration into biliary epithelial cells in biliary atresia. J Pediatr Surg 1995; 30:515–518 [View Article][PubMed]
     [Google Scholar]
  17. Barzon L, Lavezzo E, Militello V, Toppo S, Palù G. Applications of next-generation sequencing technologies to diagnostic virology. Int J Mol Sci 2011; 12:7861–7884 [View Article][PubMed]
     [Google Scholar]
  18. Isakov O, Modai S, Shomron N. Pathogen detection using short-RNA deep sequencing subtraction and assembly. Bioinformatics 2011; 27:2027–2030 [View Article][PubMed]
     [Google Scholar]
  19. Kerr TA, Korenblat KM, Davidson NO. Micrornas and liver disease. Transl Res 2011; 157:241–252 [View Article][PubMed]
     [Google Scholar]
  20. Kearns AM, Guiver M, James V, King J. Development and evaluation of a real-time quantitative PCR for the detection of human cytomegalovirus. J Virol Methods 2001; 95:121–131 [View Article]
     [Google Scholar]
  21. Mattes FM, Hainsworth EG, Hassan‐Walker AF, Burroughs AK, Sweny P, Griffiths PD et al. Kinetics of cytomegalovirus load decrease in Solid‐Organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis 2005; 191:89–92 [View Article]
     [Google Scholar]
  22. Wang W-C, Lin F-M, Chang W-C, Lin K-Y, Huang H-D et al. miRExpress: analyzing high-throughput sequencing data for profiling microRNA expression. BMC Bioinform 2009; 10:328 [View Article][PubMed]
     [Google Scholar]
  23. Moreira RK, Cabral R, Cowles RA, Lobritto SJ. Biliary atresia: a multidisciplinary approach to diagnosis and management. Arch Pathol Lab Med 2012; 136:746–760 [View Article][PubMed]
     [Google Scholar]
  24. Hand NJ, Master ZR, Eauclaire SF, Weinblatt DE, Matthews RP et al. The microRNA-30 family is required for vertebrate hepatobiliary development. Gastroenterology 2009; 136:1081–1090 [View Article][PubMed]
     [Google Scholar]
  25. Rogler CE, Levoci L, Ader T, Massimi A, Tchaikovskaya T et al. MicroRNA-23b cluster microRNAs regulate transforming growth factor-beta/bone morphogenetic protein signaling and liver stem cell differentiation by targeting Smads. Hepatology 2009; 50:575–584 [View Article][PubMed]
     [Google Scholar]
  26. Santhakumar D, Forster T, Laqtom NN, Fragkoudis R, Dickinson P et al. Combined agonist-antagonist genome-wide functional screening identifies broadly active antiviral microRNAs. Proc Natl Acad Sci U S A 2010; 107:13830–13835 [View Article][PubMed]
     [Google Scholar]
  27. Egli A, Lisboa LF, O'Shea D, Asberg A, Mueller T et al. Complexity of host micro-RNA response to cytomegalovirus reactivation after organ transplantation. Am J Transplant 2016; 16:650–660 [View Article][PubMed]
     [Google Scholar]
  28. Fu Y-R, Liu X-J, Li X-J, Shen Z-zhou, Yang B et al. Microrna miR-21 attenuates human cytomegalovirus replication in neural cells by targeting Cdc25A. J Virol 2015; 89:1070–1082 [View Article][PubMed]
     [Google Scholar]
  29. Louten J, Beach M, Palermino K, Weeks M, Holenstein G. Micrornas expressed during viral infection: biomarker potential and therapeutic considerations. Biomark Insights 2015; 10:BMI.S29512–.29552 [View Article][PubMed]
     [Google Scholar]
  30. Stark TJ, Arnold JD, Spector DH, Yeo GW. High-Resolution profiling and analysis of viral and host small RNAs during human cytomegalovirus infection. J Virol 2012; 86:226–235 [View Article][PubMed]
     [Google Scholar]
  31. Bandiera S, Billie Bian C, Hoshida Y, Baumert TF, Zeisel MB. Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma. Curr Opin Virol 2016; 20:99–105
     [Google Scholar]
  32. Hand NJ, Horner AM, Master ZR, Boateng LA, LeGuen C et al. Microrna profiling identifies miR-29 as a regulator of disease-associated pathways in experimental biliary atresia. J Pediatr Gastroenterol Nutr 2012; 54:186–192 [View Article][PubMed]
     [Google Scholar]
  33. Shen W-jun, Dong R, Chen G, Zheng S. microRNA-222 modulates liver fibrosis in a murine model of biliary atresia. Biochem Biophys Res Commun 2014; 446:155–159 [View Article][PubMed]
     [Google Scholar]
  34. Anadol E, Schierwagen R, Elfimova N, Tack K, Schwarze-Zander C et al. Circulating microRNAs as a marker for liver injury in human immunodeficiency virus patients. Hepatology 2015; 61:46–55 [View Article][PubMed]
     [Google Scholar]
  35. Murray MJ, Raby KL, Saini HK, Bailey S, Wool SV et al. Solid tumors of childhood display specific serum microRNA profiles. Cancer Epidemiol Biomarkers Prev 2015; 24:350–360 [View Article][PubMed]
     [Google Scholar]
  36. Church RJ, Otieno M, McDuffie JE, Singh B, Sonee M et al. Beyond miR-122: identification of microRNA alterations in blood during a time course of hepatobiliary injury and biliary hyperplasia in rats. Toxicol Sci 2016; 150:3–14 [View Article][PubMed]
     [Google Scholar]
  37. Girard M, Lacaille F. Diagnosis of neonatal cholestasis. Ann Nestlé [Engl] 2008; 66:109–120 [View Article]
     [Google Scholar]
  38. Bandiera S, Pfeffer S, Baumert TF, Zeisel MB. miR-122--a key factor and therapeutic target in liver disease. J Hepatol 2015; 62:448–457 [View Article][PubMed]
     [Google Scholar]
  39. Trebicka J, Anadol E, Elfimova N, Strack I, Roggendorf M et al. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol 2013; 58:234–239 [View Article][PubMed]
     [Google Scholar]
  40. Kitano M, Bloomston P. Hepatic stellate cells and microRNAs in pathogenesis of liver fibrosis. JCM 2016; 5:38 [View Article]
     [Google Scholar]
  41. Yu D, Tolleson WH, Knox B, Jin Y, Guo L et al. Modulation of Aldh5a1 and Slc22a7 by microRNA hsa-miR-29a-3p in human liver cells. Biochem Pharmacol 2015; 98:671–680 [View Article][PubMed]
     [Google Scholar]
  42. Murakami Y, Kawada N. Micrornas in hepatic pathophysiology. Hepatol Res 2017; 47:60–69 [View Article][PubMed]
     [Google Scholar]
  43. Wang J-Y, Cheng H, Zhang H-Y, Ye Y-Q, Feng Q et al. Suppressing microRNA-29c promotes biliary atresia-related fibrosis by targeting Dnmt3a and Dnmt3b. Cell Mol Biol Lett 2019; 24:10 [View Article][PubMed]
     [Google Scholar]
  44. Szabo G, Bala S. Micrornas in liver disease. Nature 2013; 10:542–552
     [Google Scholar]
  45. Kriegel AJ, Liu Y, Fang Y, Ding X, Liang M. The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol Genomics 2012; 44:237–244 [View Article][PubMed]
     [Google Scholar]
  46. Li F, Ma N, Zhao R, Wu G, Zhang Y et al. Overexpression of miR-483-5p/3p cooperate to inhibit mouse liver fibrosis by suppressing the TGF-β stimulated HSCs in transgenic mice. J Cell Mol Med 2014; 18:966–974 [View Article][PubMed]
     [Google Scholar]
  47. Chen L, Chen R, Kemper S, Cong M, You H et al. Therapeutic effects of serum extracellular vesicles in liver fibrosis. J Extracell Vesicles 2018; 7:1461505 [View Article][PubMed]
     [Google Scholar]
  48. Murakami Y, Toyoda H, Tanaka M, Kuroda M, Harada Y et al. The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS One 2011; 6:e16081 [View Article][PubMed]
     [Google Scholar]
  49. Zheng J, Wu C, Xu Z, Xia P, Dong P et al. Hepatic stellate cell is activated by microRNA-181b via PTEN/AKT pathway. Mol Cell Biochem 2015; 398:1–9 [View Article][PubMed]
     [Google Scholar]
  50. Yu F, Lu Z, Chen B, Dong P, Zheng J. Identification of a novel lincRNA-p21-miR-181b-PTEN signaling cascade in liver fibrosis. Mediators Inflamm 2016; 2016:110 [View Article][PubMed]
     [Google Scholar]
  51. Brockhausen J, Tay SS, Grzelak CA, Bertolino P, Bowen DG et al. miR-181A mediates TGF-β-induced hepatocyte EMT and is dysregulated in cirrhosis and hepatocellular cancer. Liver Int 2015; 35:240–253 [View Article][PubMed]
     [Google Scholar]
  52. Shigehara K, Yokomuro S, Ishibashi O, Mizuguchi Y, Arima Y et al. Real-Time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer. PLoS One 2011; 6:e23584 [View Article][PubMed]
     [Google Scholar]
  53. Verhoeven CJ, Metselaar HJ, van der Laan LJW. Barking up the wrong tree: microRNAs in bile as markers for biliary complications. Liver Transpl 2014; 20:637–639 [View Article][PubMed]
     [Google Scholar]
  54. Caserta S, Kern F, Cohen J, Drage S, Newbury SF et al. Circulating plasma microRNAs can differentiate human sepsis and systemic inflammatory response syndrome (SIRS). Sci Rep 2016; 6:28006 [View Article][PubMed]
     [Google Scholar]
  55. Ji X, Wu B, Fan J, Han R, Luo C et al. The anti-fibrotic effects and mechanisms of MicroRNA-486-5p in pulmonary fibrosis. Sci Rep 2015; 5:14131 [View Article][PubMed]
     [Google Scholar]
  56. Viñas JL, Burger D, Zimpelmann J, Haneef R, Knoll W et al. Transfer of microRNA-486-5p from human endothelial colony forming cell-derived exosomes reduces ischemic kidney injury. Kidney Int 2016; 90:1238–1250 [View Article][PubMed]
     [Google Scholar]
  57. Collino F, Bruno S, Incarnato D, Dettori D, Neri F et al. AKI recovery induced by mesenchymal stromal cell-derived extracellular vesicles carrying microRNAs. J Am Soc Nephrol 2015; 26:2349–2360 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/acmi/10.1099/acmi.0.000127
Loading
Using next-generation sequencing of microRNAs to identify host and/or pathogen nucleic acid signatures in samples from children with biliary atresia – a pilot study
Access Microbiology 2, e000127 (2020); https://doi.org/10.1099/acmi.0.000127
/content/journal/acmi/10.1099/acmi.0.000127
/content/journal/acmi/10.1099/acmi.0.000127
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error